JP2000508322A - バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法 - Google Patents
バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法Info
- Publication number
- JP2000508322A JP2000508322A JP9536607A JP53660797A JP2000508322A JP 2000508322 A JP2000508322 A JP 2000508322A JP 9536607 A JP9536607 A JP 9536607A JP 53660797 A JP53660797 A JP 53660797A JP 2000508322 A JP2000508322 A JP 2000508322A
- Authority
- JP
- Japan
- Prior art keywords
- bacteriophage
- bacterial
- host
- preparation
- phage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001515965 unidentified phage Species 0.000 title claims abstract description 197
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 208000035473 Communicable disease Diseases 0.000 title description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 130
- 244000005700 microbiome Species 0.000 claims abstract description 77
- 230000001580 bacterial effect Effects 0.000 claims abstract description 73
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 32
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 32
- 238000009472 formulation Methods 0.000 claims abstract description 15
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 230000003115 biocidal effect Effects 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims description 43
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 241000589886 Treponema Species 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 241000588923 Citrobacter Species 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 18
- 241000588748 Klebsiella Species 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 241000589516 Pseudomonas Species 0.000 claims description 9
- 241000295644 Staphylococcaceae Species 0.000 claims description 9
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 9
- 241000588722 Escherichia Species 0.000 claims description 8
- 241000186359 Mycobacterium Species 0.000 claims description 8
- 241000607142 Salmonella Species 0.000 claims description 8
- 241000607768 Shigella Species 0.000 claims description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims description 8
- 241000588914 Enterobacter Species 0.000 claims description 7
- 241000589989 Helicobacter Species 0.000 claims description 7
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 6
- 241000186429 Propionibacterium Species 0.000 claims description 6
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 241000186427 Cutibacterium acnes Species 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 241000187474 Mycobacterium asiaticum Species 0.000 claims description 4
- 241000186362 Mycobacterium leprae Species 0.000 claims description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 241000194019 Streptococcus mutans Species 0.000 claims description 4
- 241000194025 Streptococcus oralis Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- -1 monobactams Chemical class 0.000 claims description 4
- 231100000219 mutagenic Toxicity 0.000 claims description 4
- 230000003505 mutagenic effect Effects 0.000 claims description 4
- 229940055019 propionibacterium acne Drugs 0.000 claims description 4
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 4
- 241000589968 Borrelia Species 0.000 claims description 3
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 241000186364 Mycobacterium intracellulare Species 0.000 claims description 3
- 241000204048 Mycoplasma hominis Species 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000607764 Shigella dysenteriae Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000193991 Streptococcus parasanguinis Species 0.000 claims description 3
- 241000589884 Treponema pallidum Species 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 3
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- 229940041009 monobactams Drugs 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 150000007660 quinolones Chemical class 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000588653 Neisseria Species 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 208000020154 Acnes Diseases 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 abstract description 18
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000001018 virulence Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000001066 phage therapy Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000010865 sewage Substances 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000283068 Tapiridae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940090589 keflex Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1566396P | 1996-04-15 | 1996-04-15 | |
| US60/015,663 | 1996-04-15 | ||
| PCT/CA1997/000250 WO1997039111A1 (en) | 1996-04-15 | 1997-04-15 | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000508322A true JP2000508322A (ja) | 2000-07-04 |
| JP2000508322A5 JP2000508322A5 (enExample) | 2004-12-09 |
Family
ID=21772776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9536607A Pending JP2000508322A (ja) | 1996-04-15 | 1997-04-15 | バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6121036A (enExample) |
| EP (1) | EP0895534A1 (enExample) |
| JP (1) | JP2000508322A (enExample) |
| AU (1) | AU734420B2 (enExample) |
| CA (1) | CA2251724A1 (enExample) |
| WO (1) | WO1997039111A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007084492A (ja) * | 2005-09-22 | 2007-04-05 | Hiroshima Univ | バクテリオファージを含む、細菌性感染症治療用の薬剤 |
| JP2008526892A (ja) * | 2005-01-10 | 2008-07-24 | オムニライティックス・インコーポレーテッド | 食品の処理方法 |
| JP2010521428A (ja) * | 2007-03-09 | 2010-06-24 | バイオコントロール リミテッド | バクテリオファージ治療の有益な効果 |
| JP2011050373A (ja) * | 2008-12-26 | 2011-03-17 | Wako Pure Chem Ind Ltd | スタフィロコッカス・アウレウス溶菌性バクテリオファージ |
| KR20180137815A (ko) * | 2017-06-19 | 2018-12-28 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR20180137813A (ko) * | 2017-06-19 | 2018-12-28 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR20190000944A (ko) * | 2017-06-19 | 2019-01-04 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| JP2022536960A (ja) * | 2019-06-21 | 2022-08-22 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｌｉｓｔｅｒｉａの検出のための変異体バクテリオファージを生成するための方法 |
| JP2023516762A (ja) * | 2020-03-06 | 2023-04-20 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌感染症を治療するための組成物及び方法 |
| JP2023517057A (ja) * | 2020-03-06 | 2023-04-21 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌感染症を治療するための組成物及び方法 |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0895534A1 (en) * | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| GB9809414D0 (en) * | 1998-05-02 | 1998-07-01 | Scottish Crop Research Inst | Method |
| GB9908195D0 (en) | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| US6440405B1 (en) * | 1999-06-07 | 2002-08-27 | University Of Delaware | Quaternary ammonium functionalized dendrimers and methods of use therefor |
| US20040191224A1 (en) * | 2000-01-11 | 2004-09-30 | Intralytix, Inc. | Method and device for sanitation using bacteriophages |
| WO2001050872A2 (en) | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Method for produce sanitation using bacteriophages |
| US6485902B2 (en) | 2000-06-06 | 2002-11-26 | Thomas E. Waddell | Use of bacteriophages for control of escherichia coli O157 |
| DE10042853A1 (de) * | 2000-08-30 | 2002-04-25 | Florian Lang | Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen |
| AU2002221713A1 (en) * | 2000-10-25 | 2002-05-06 | Intercell Biomedizinische Forschulungs- Und Entwicklungs Ag | Modified phage, comprising a non-lytic modification and expressing a kil-gene |
| US6656463B2 (en) * | 2000-11-13 | 2003-12-02 | Iowa State University Research Foundation, Inc. | Compositions and methods for reducing the amount of salmonella in livestock |
| US6461608B1 (en) * | 2000-11-22 | 2002-10-08 | Nymox Pharmaceutical Corporation | Bacteriophage composition useful in treating food products to prevent bacterial contamination |
| DE10115310A1 (de) * | 2001-03-28 | 2002-10-10 | Nodar A Daniela | Bakteriophagen-Präparation |
| AU2002308467A1 (en) * | 2001-04-19 | 2002-11-05 | Biophage, Inc. | Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
| PL354822A1 (en) * | 2002-06-30 | 2004-01-12 | Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu | Method of receiving purified bacteriophage preparations and new applications of polysaccharide or its esterificated derivative |
| US7232564B2 (en) * | 2001-07-18 | 2007-06-19 | Instytut Immunologii I Terapii Doswiadczal-Nej Pan | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections |
| BR0214928A (pt) * | 2001-12-13 | 2004-11-30 | Nestle Sa | Fagos isolados e seu uso em produtos alimentares e rações para animais |
| US6759229B2 (en) * | 2001-12-18 | 2004-07-06 | President & Fellows Of Harvard College | Toxin-phage bacteriocide antibiotic and uses thereof |
| CA2478636A1 (en) * | 2002-03-04 | 2003-09-12 | Nymox Corporation | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
| US7514407B2 (en) * | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
| GB0207021D0 (en) * | 2002-03-25 | 2002-05-08 | Univ Warwick | Anti-bacterial agents |
| DK1504088T3 (da) * | 2002-03-25 | 2007-12-17 | Univ Warwick | Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner |
| WO2003103578A2 (en) * | 2002-06-05 | 2003-12-18 | Iowa State University Research Foundation, Inc. | Bacteriophage and enzymes lytic to salmonellae |
| RU2232808C1 (ru) * | 2002-10-11 | 2004-07-20 | Закрытое акционерное общество "ПИ - ПРО - ЛАЙФ" | Биопрепарат на основе бактериофагов для профилактики и лечения сальмонеллеза животных |
| RU2244747C2 (ru) * | 2002-11-01 | 2005-01-20 | Закрытое акционерное общество "ПИ-ПРО-ЛАЙФ" | Биопрепарат на основе бактериофагов для профилактики и лечения колибактериоза (эшерихиоза) животных |
| EP1560491A4 (en) * | 2002-11-14 | 2008-04-30 | Gangagen Inc | BACTERIOPHAGE WITH MODIFIED HOLIN AND ITS USE |
| GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
| AU2004258731B2 (en) | 2003-07-23 | 2010-02-25 | Biocontrol Limited | Bacteriophage-containing therapeutic agents |
| WO2005046579A2 (en) * | 2003-10-06 | 2005-05-26 | Gangagen, Inc. | Defined dose therapeutic phage |
| CA2614800C (en) * | 2005-07-12 | 2018-10-30 | The University Of Leeds | Bacteriophage specifically for lysing propionibacterium acnes and uses thereof |
| US20090053179A1 (en) * | 2005-10-05 | 2009-02-26 | Internalle, Inc. | Method for using liberated dormant bacteriophage and environmental stress to reduce infectious bacteria |
| US20070173787A1 (en) * | 2005-11-01 | 2007-07-26 | Huang Mark C T | Thin-film nitinol based drug eluting stent |
| WO2007113657A1 (en) | 2006-04-04 | 2007-10-11 | Centre National De La Recherche Scientifique - Cnrs | Process of production of bacteriophage compositions and methods in phage therapy field |
| US20070292397A1 (en) * | 2006-06-19 | 2007-12-20 | Mcnulty Amy K | Method for the detection and neutralization of bacteria |
| KR100781669B1 (ko) * | 2006-06-20 | 2007-12-03 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균 특이적 사멸능을 갖는 박테리오파지 |
| KR100759988B1 (ko) * | 2006-08-04 | 2007-09-19 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균에 특이적인 항균 단백질 |
| KR100924661B1 (ko) * | 2007-08-16 | 2009-11-03 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균 특이적 사멸능을 갖는 포도비리대박테리오파지 |
| KR100910961B1 (ko) | 2007-09-13 | 2009-08-05 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질 |
| US8956628B2 (en) * | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
| RU2366456C1 (ru) * | 2007-12-17 | 2009-09-10 | Николай Васильевич Пименов | Препарат против сальмонеллеза голубей и способ лечения сальмонеллеза голубей |
| GB0800149D0 (en) * | 2008-01-04 | 2008-02-13 | Novolytics Ltd | Improved host range phage |
| RU2375075C1 (ru) * | 2008-04-24 | 2009-12-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН (ВИЭВ) | Способ лечения птиц при сальмонеллезе, вызванном salmonella typhimurium |
| US7745194B2 (en) * | 2008-09-16 | 2010-06-29 | Intralytix, Inc. | Staphylococcus aureus: bacteriophage and uses thereof |
| KR101070938B1 (ko) * | 2008-12-02 | 2011-10-06 | 씨제이제일제당 (주) | 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| GB2466177A (en) * | 2008-12-03 | 2010-06-16 | Arab Science & Technology Found | Bacteriophage selection and breeding |
| US8771936B2 (en) | 2008-12-24 | 2014-07-08 | Cj Cheiljedang Corporation | Bacteriophage and antibacterial composition comprising the same |
| KR101151516B1 (ko) * | 2008-12-24 | 2012-05-30 | 씨제이제일제당 (주) | 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| US8377866B2 (en) * | 2009-02-12 | 2013-02-19 | Intron Biotechnology, Inc. | Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus |
| US8043613B2 (en) * | 2009-02-12 | 2011-10-25 | Intron Biotechnology, Inc. | Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus |
| US20120276612A1 (en) | 2009-08-12 | 2012-11-01 | Tzu Chi Buddhist General Hospital | Phage of acinetobacter baumannii |
| WO2011028061A2 (en) * | 2009-09-03 | 2011-03-10 | Cj Cheiljedang Corporation | Novel bacteriophage and antibacterial composition comprising the same |
| US8293515B2 (en) * | 2009-09-03 | 2012-10-23 | CJ Cheijedang Corporation | Salmonella bacteriophage and antibacterial composition comprising the same |
| EP2475377B1 (en) * | 2009-09-03 | 2016-01-06 | CJ CheilJedang Corporation | Novel bacteriophage and antibacterial composition comprising the same |
| US20110052543A1 (en) * | 2009-09-03 | 2011-03-03 | Cj Cheiljedang Corporation | Novel bacteriophage and antibacterial composition comprising the same |
| US8846368B2 (en) | 2009-09-03 | 2014-09-30 | Cj Cheiljedang Corporation | Bacteriophage and antibacterial composition comprising the same |
| KR101101377B1 (ko) | 2009-10-16 | 2012-01-02 | 경희대학교 산학협력단 | 이질균에 특이적 사멸능을 갖는 박테리오파지 |
| TW201130980A (en) * | 2010-03-02 | 2011-09-16 | Univ Ishou | A new lytic phage specific to Klebsiella pneumoniae |
| PT2616087T (pt) | 2010-09-17 | 2018-12-20 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos |
| US8597928B2 (en) | 2010-12-21 | 2013-12-03 | Cj Cheiljedang Corporation | Bacteriophage of the siphoviridae family and antibacterial compositions comprising the same |
| KR101432872B1 (ko) | 2011-09-20 | 2014-08-27 | 씨제이제일제당 (주) | 신규 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR101279780B1 (ko) | 2011-10-05 | 2013-06-28 | 주식회사 인트론바이오테크놀로지 | 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지 |
| KR101260645B1 (ko) | 2011-11-14 | 2013-05-03 | 씨제이제일제당 (주) | 대장균 특이적 사멸능을 나타내는 신규 분리된 박테리오파지 및 이를 포함하는 항균 조성물 |
| WO2013142378A1 (en) | 2012-03-17 | 2013-09-26 | The Regents Of The University Of California | Fast diagnosis and personalized treatments for acne |
| KR101299179B1 (ko) * | 2012-04-18 | 2013-08-22 | 씨제이제일제당 (주) | 신규 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR102310387B1 (ko) * | 2012-05-09 | 2021-10-13 | 콘트라펙트 코포레이션 | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 |
| WO2014150870A2 (en) | 2013-03-15 | 2014-09-25 | Altria Client Services Inc. | Bacteriophage and methods of making and using |
| KR101591783B1 (ko) * | 2014-04-15 | 2016-02-04 | 씨제이제일제당(주) | 신규 박테리오파지 및 이를 포함하는 조성물 |
| RU2565559C1 (ru) * | 2014-11-19 | 2015-10-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | ШТАММ БАКТЕРИОФАГА Citrobacter freundii CF17, СПОСОБНЫЙ ЛИЗИРОВАТЬ ПАТОГЕННЫЕ ШТАММЫ CITROBACTER FREUNDII |
| US10357056B2 (en) | 2015-01-29 | 2019-07-23 | Altria Client Services Llc | Endolysin from bacteriophage against Geobacillus and methods of using |
| US9781929B2 (en) | 2015-01-29 | 2017-10-10 | Altria Client Services Llc | Bacteriophage and methods of using |
| US11058131B2 (en) | 2015-04-16 | 2021-07-13 | Kennesaw State University Research And Service Foundation, Inc. | Escherichia coli O157:H7 bacteriophage Φ241 |
| KR102586835B1 (ko) | 2021-02-23 | 2023-10-10 | 씨제이제일제당 주식회사 | 장독소성 대장균에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR102586836B1 (ko) | 2021-02-23 | 2023-10-10 | 씨제이제일제당 주식회사 | 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR102586837B1 (ko) | 2021-02-23 | 2023-10-10 | 씨제이제일제당 주식회사 | 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR102586838B1 (ko) * | 2021-02-25 | 2023-10-10 | 씨제이제일제당 주식회사 | 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| KR102586839B1 (ko) | 2021-02-25 | 2023-10-10 | 씨제이제일제당 주식회사 | 클로스트리디움 퍼프린젠스에 대한 특이적인 사멸능을 가지는 신규한 박테리오파지 및 이를 포함하는 항균 조성물 |
| CN119799652A (zh) * | 2024-11-29 | 2025-04-11 | 瑞科盟(青岛)生物工程有限公司 | 一株产酸克雷伯菌噬菌体rdp-ec-23031及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957686A (en) * | 1990-02-06 | 1990-09-18 | Norris Alan H | Use of bacteriophages to inhibit dental caries |
| JPH03118306A (ja) * | 1989-08-21 | 1991-05-20 | Unilever Nv | 望ましくない微生物に対するウイルスの使用 |
| WO1995027043A1 (en) * | 1994-04-05 | 1995-10-12 | Exponential Biotherapies, Inc. | Antibacterial therapy with genotypically modified bacteriophage |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851006A (en) * | 1955-11-03 | 1958-09-09 | Swift & Co | Hatching of eggs |
| GB829266A (en) * | 1957-03-20 | 1960-03-02 | Biogena | A method of manufacturing bacteriophages in solid dry form |
| US3793151A (en) * | 1972-07-10 | 1974-02-19 | J Denney | Method of screening for anticapsular substances |
| SU827064A1 (ru) * | 1979-05-17 | 1981-05-07 | Центральный Научно-Исследовательскийордена Ленина И Ордена Трудового Красногознамени Институт Гематологии И Переливаниякрови | Способ профилактики эндогенногоиНфициРОВАНи пРи ОСТРыХ лЕйКОзАХ |
| US4659561A (en) * | 1983-02-18 | 1987-04-21 | The University Of Vermont And State Agricultural College | Process for treating the oral cavity |
| SU1153330A1 (ru) * | 1983-11-05 | 1985-04-30 | Предприятие П/Я В-8542 | Устройство дл делени многочлена на многочлен |
| US4674480A (en) * | 1984-05-25 | 1987-06-23 | Lemelson Jerome H | Drug compositions and methods of applying same |
| US4678750A (en) * | 1984-10-18 | 1987-07-07 | Microlife Technics, Inc. | Method and compositions for use in the treatment of fireblight |
| US4828999A (en) * | 1986-07-21 | 1989-05-09 | Jackson Le Roy E | Bacteriophage prevention and control of harmful plant bacteria |
| WO1990003122A1 (en) * | 1988-09-26 | 1990-04-05 | Microbial Developments Limited | Antimicrobial preparations |
| US4891210A (en) * | 1989-01-03 | 1990-01-02 | Norris Alan H | Use of bacteriophages in dental hygiene |
| GB8913657D0 (en) * | 1989-06-14 | 1989-08-02 | Microbial Dev Ltd | Ruminant feedstuff additives |
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| SU1685998A1 (ru) * | 1989-10-11 | 1991-10-23 | Научно-Производственное Объединение "Бактериофаг" Тбилисского Научно-Исследовательского Института Вакцин И Сывороток | Штамм бактериофага ЕNтеRовастеR aeRoGeNeS дл диагностики, профилактики и лечени инфекции, вызываемой ЕNтеRовастеR aeRoGeNeS |
| ES2016539A6 (es) * | 1989-10-18 | 1990-11-01 | Diseno Y Construccion De Mecan | Aparato extracor de piezas moldeadas, en especial para maquinas de inyectar plastico. |
| GB2253859A (en) * | 1991-02-28 | 1992-09-23 | Microbial Dev Ltd | Use of bacteriophages to prevent microbial infestation |
| RU2036232C1 (ru) * | 1992-03-02 | 1995-05-27 | Уфимский научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова | Способ получения пиобактериофага |
| DE699079T1 (de) * | 1994-03-07 | 1997-09-25 | Dendritech Inc | Bioaktive und/oder gezielte dendrimere-konjugate |
| US5811093A (en) * | 1994-04-05 | 1998-09-22 | Exponential Biotherapies, Inc. | Bacteriophage genotypically modified to delay inactivations by the host defense system |
| CA2199478A1 (en) * | 1994-09-09 | 1996-03-14 | Allan L. Delisle | Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases |
| US5656424A (en) * | 1995-02-15 | 1997-08-12 | Albert Einstein College Of Medicine, A Division Of Yeshiva University | Identification of mycobacterium tuberculosis complex species |
| US5741697A (en) * | 1995-11-30 | 1998-04-21 | University Of Rochester | Bacteriophage of chlamydia psittaci |
| EP0895534A1 (en) * | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US6322783B1 (en) * | 1996-08-26 | 2001-11-27 | Seishi Takahashi | Bacteriophages, method for screening same and bactericidal compositions using same, and detection kits using same |
| US6254866B1 (en) * | 1997-10-31 | 2001-07-03 | New Horizons Diagnostics Corporation | Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract |
| US6432444B1 (en) * | 1997-10-31 | 2002-08-13 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymes for treating dermatological infections |
| US6277399B1 (en) * | 1997-10-31 | 2001-08-21 | New Horizon Diagnostics Corporation | Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections |
| US6264945B1 (en) * | 1997-10-31 | 2001-07-24 | Vincent A Fischetti | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| US6248324B1 (en) * | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6056954A (en) * | 1997-10-31 | 2000-05-02 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses |
| US6982153B1 (en) * | 1998-12-03 | 2006-01-03 | Targanta Therapeutics, Inc. | DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides |
| US6482632B1 (en) * | 1999-03-29 | 2002-11-19 | Council Of Scientic And Industrial Research | Bacteriophage, a process for the isolation thereof, and a universal growth medium useful in the process thereof |
| US6271359B1 (en) * | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| WO2001050872A2 (en) * | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Method for produce sanitation using bacteriophages |
| US6485902B2 (en) * | 2000-06-06 | 2002-11-26 | Thomas E. Waddell | Use of bacteriophages for control of escherichia coli O157 |
| AU2001278003A1 (en) * | 2000-07-25 | 2002-02-05 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Bacteriophage having multiple host range |
| US6991786B1 (en) * | 2000-08-30 | 2006-01-31 | Wisconsin Alumni Research Foundation | Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics |
| US6656463B2 (en) * | 2000-11-13 | 2003-12-02 | Iowa State University Research Foundation, Inc. | Compositions and methods for reducing the amount of salmonella in livestock |
| US6461608B1 (en) * | 2000-11-22 | 2002-10-08 | Nymox Pharmaceutical Corporation | Bacteriophage composition useful in treating food products to prevent bacterial contamination |
| CA2474159A1 (en) * | 2002-01-23 | 2003-05-21 | Carl R. Merril | Method for determining sensitivity to a bacteriophage |
| EP1487273B1 (en) * | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
| US20040157314A1 (en) * | 2003-02-07 | 2004-08-12 | Phagetech Inc. | Inhibitors of Staphylococcus aureus primary sigma factor and uses thereof |
| US7550283B2 (en) * | 2003-04-10 | 2009-06-23 | Salisbury University | Bacteriophage for lysis of Methylobacterium and compositions and uses thereof |
| US7521201B2 (en) * | 2004-11-01 | 2009-04-21 | Strategic Diagnostics Inc. | Bacteriophages as selective agents |
-
1997
- 1997-04-15 EP EP97916278A patent/EP0895534A1/en not_active Ceased
- 1997-04-15 WO PCT/CA1997/000250 patent/WO1997039111A1/en not_active Ceased
- 1997-04-15 AU AU25000/97A patent/AU734420B2/en not_active Ceased
- 1997-04-15 US US08/842,653 patent/US6121036A/en not_active Expired - Lifetime
- 1997-04-15 CA CA002251724A patent/CA2251724A1/en not_active Abandoned
- 1997-04-15 JP JP9536607A patent/JP2000508322A/ja active Pending
-
2000
- 2000-05-31 US US09/583,738 patent/US6942858B1/en not_active Expired - Fee Related
-
2005
- 2005-07-27 US US11/189,819 patent/US20050260171A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03118306A (ja) * | 1989-08-21 | 1991-05-20 | Unilever Nv | 望ましくない微生物に対するウイルスの使用 |
| US4957686A (en) * | 1990-02-06 | 1990-09-18 | Norris Alan H | Use of bacteriophages to inhibit dental caries |
| WO1995027043A1 (en) * | 1994-04-05 | 1995-10-12 | Exponential Biotherapies, Inc. | Antibacterial therapy with genotypically modified bacteriophage |
Non-Patent Citations (1)
| Title |
|---|
| H.WILLIAMS SMITH. ET AL.,: "The control of exmeprimental Escherichia coli diarrhoea in calves by means of becteriophages.", JOURNAL OF GENERAL MICROBIOLOGY, vol. 133, JPN7007000681, 1987, pages 1111 - 1126, ISSN: 0000916159 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008526892A (ja) * | 2005-01-10 | 2008-07-24 | オムニライティックス・インコーポレーテッド | 食品の処理方法 |
| JP2007084492A (ja) * | 2005-09-22 | 2007-04-05 | Hiroshima Univ | バクテリオファージを含む、細菌性感染症治療用の薬剤 |
| JP2010521428A (ja) * | 2007-03-09 | 2010-06-24 | バイオコントロール リミテッド | バクテリオファージ治療の有益な効果 |
| JP2014237685A (ja) * | 2007-03-09 | 2014-12-18 | バイオコントロール リミテッド | バクテリオファージ治療の有益な効果 |
| JP2011050373A (ja) * | 2008-12-26 | 2011-03-17 | Wako Pure Chem Ind Ltd | スタフィロコッカス・アウレウス溶菌性バクテリオファージ |
| KR20180137813A (ko) * | 2017-06-19 | 2018-12-28 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR20180137815A (ko) * | 2017-06-19 | 2018-12-28 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR20190000944A (ko) * | 2017-06-19 | 2019-01-04 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR101940019B1 (ko) | 2017-06-19 | 2019-01-18 | 연세대학교 산학협력단 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR102011965B1 (ko) | 2017-06-19 | 2019-08-19 | 주식회사 마이크로바이오틱스 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| KR102011956B1 (ko) | 2017-06-19 | 2019-08-19 | 주식회사 마이크로바이오틱스 | 항생제 내성을 갖는 클렙시엘라(Klebsiella)속 균을 용균하는 박테리오파지 |
| JP2022536960A (ja) * | 2019-06-21 | 2022-08-22 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｌｉｓｔｅｒｉａの検出のための変異体バクテリオファージを生成するための方法 |
| JP2023516762A (ja) * | 2020-03-06 | 2023-04-20 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌感染症を治療するための組成物及び方法 |
| JP2023517057A (ja) * | 2020-03-06 | 2023-04-21 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌感染症を治療するための組成物及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU734420B2 (en) | 2001-06-14 |
| EP0895534A1 (en) | 1999-02-10 |
| US6121036A (en) | 2000-09-19 |
| US6942858B1 (en) | 2005-09-13 |
| CA2251724A1 (en) | 1997-10-23 |
| US20050260171A1 (en) | 2005-11-24 |
| WO1997039111A1 (en) | 1997-10-23 |
| AU2500097A (en) | 1997-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000508322A (ja) | バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法 | |
| US7588929B2 (en) | Production of bacteriophage compositions for use in phage therapy | |
| JP4834544B2 (ja) | インタクトな細菌ミニセルを精製するための薬学的に適合可能な方法 | |
| JP5127708B2 (ja) | バクテリオファージ及びその使用 | |
| BR112016009062B1 (pt) | Composição antibacteriana, método para a preparação de uma composição, método in vitro para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo e método in vitro para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos | |
| EP1406642B1 (en) | Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections | |
| JP7370867B2 (ja) | 療法バクテリオファージ組成物 | |
| CN115029322B (zh) | 一株多药耐药肺炎克雷伯菌噬菌体及其应用 | |
| Maharjan et al. | Isolation and characterization of lytic bacteriophage against multi-drug resistant Pseudomonas aeruginosa | |
| Tee et al. | A newly isolated Pseudomonas otitidis phage, vB_PotS-PotUPM1 from tilapia in Malaysia | |
| Fayez et al. | Topically applied bacteriophage to control multi-drug resistant Klebsiella pneumoniae infected wound in a rat model. Antibiotics. 2021; 10 (9): 1048 | |
| Koshy et al. | Synergistic effect of phage-antibiotic combination against Stenotrophomonas maltophilia | |
| Nair et al. | The prospects of a highly virulent biofilm dispersing bacteriophage isolated from environment for controlling Enterobacter cloacae in clinical medicine | |
| US20250002869A1 (en) | Burkholderia pseudomallei (Bp) phage vB BpP HN01 and use thereof | |
| CN120324475B (zh) | 一种治疗或预防伴侣动物高危克隆株的噬菌体鸡尾酒组合及其应用 | |
| Pallavali et al. | Isolation and characterization of a lytic bacteriophage (VB_PAnP_PADP4) against MDR-Pseudomonas aeruginosa isolated from septic wound infections | |
| Almelan et al. | Isolation and characterization of bacteriophage targeting Enterococcus faecalis isolated from root canal infection (in vitro study) | |
| Azeez et al. | Isolation of Lytic Acinetobacter Baumannii Phage VB_Acib_C_A10 from Iraq Pond Waters and Comparing Its Antibacterial Effect with Cefotaxime Antibiotic | |
| Frantar et al. | Isolation and characterization of two novel oral bacteriophages with anti-biofilm activity against Cutibacterium acnes | |
| Tee et al. | Isolation and Characterization of Highly Lytic Bacteriophages against Staphylococcus aureus in Malaysian Sewage Water. | |
| Davison et al. | Isolation of Bacteriophage against Pseudomonas aureginosa from Male Urinary Tract Infection (UTI) Specimen | |
| CN120866235A (zh) | 一株新型烈性副溶血性弧菌噬菌体vB_VpS_CC6及其应用 | |
| CN119552826A (zh) | 肺炎克雷伯氏菌噬菌体及其应用 | |
| CN118792265A (zh) | 一种噬菌体a149及其在拮抗耐万古霉素粪肠球菌中的应用 | |
| Alharby | Isolation and characterization of a novel bacteriophage, ASC10, that lyses Francisella tularensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040407 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080131 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080507 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080708 |